Wyeth Alters R&D to Address the Emerging Challenges Facing Biotech
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 82 (Table of Contents)
Published: 7 Apr-2007
DOI: 10.3833/pdr.v2007.i82.364 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
Wyeth is transforming its R&D pipeline in order to plug its looming patent expiry hole and to remain as a dominant force among big pharma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018